Constructing an Insulin-Like Growth Factor-based Prediction Model (NCT00263445) | Clinical Trial Compass
TerminatedNot Applicable
Constructing an Insulin-Like Growth Factor-based Prediction Model
Stopped: Insufficient recruitment
United States30 participantsStarted 2004-08
Plain-language summary
Serum insulin-like growth factor-I (IGF-I) measurements have been shown to correlate well with growth hormone action and effect, and recent data show that serum IGF-I may be related to safety and efficacy of growth hormone (GH) treatment in patients. Some studies indicate that high IGF-I levels are associated with increased cancer risk, and low IGF-I levels are associated with increased risk for cardiovascular disease. Studies in children also show that the serum IGF-I level is correlated with the change in height score achieved (that is, the higher the IGF-I level, the greater the gain in height). Pediatric endocrinologists have therefore begun to use serum IGF-I levels, in addition to growth rate and weight gain, to adjust the GH dose in treated children.
Although monitoring of serum IGF-I levels is becoming standard of care in patients begin treated with GH, there are few guidelines regarding the actual logistics of adjusting GH dose. As serum IGF-I level has been linked to both safety and efficacy of GH treatment, the ideal practice would be to maintain serum IGF-I levels within a certain target range. The overall goal of our study is to construct a mathematical model which predicts the change in GH dose necessary to achieve a desired change in IGF-I level.
Hypotheses to be tested by our study include the following: IGF-I measurement has a role in optimization of GH therapy; GH dose change to achieve IGF-I changes are predictable; and gender and puberty affect the relationship between dose change and target IGF-I changes.
Who can participate
Age range
3 Years – 14 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Prepubertal patients,
* Male/female,
* Ages 3-14 yrs,
* Being treated with growth hormone for the conditions of growth hormone deficiency, idiopathic short stature, and small-for-gestational age with failure to catch up to the normal growth curve by age 2 years.
Exclusion Criteria:
* Patients being treated with growth hormone for other conditions such as Turner syndrome, chronic renal failure, or Prader-Willi syndrome
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was terminated before completion — can you tell me why it was stopped early, and what that means for the reliability of any findings about IGF-1 as a predictor of growth hormone treatment response?
2Since this study was measuring changes in IGF-1 SDS scores across three different conditions — growth hormone deficiency, idiopathic short stature, and small for gestational age — does the fact that it didn't finish affect how you currently interpret my child's IGF-1 levels when planning treatment?
3Because this was listed as 'Phase NA' and appears to be a observational or modeling study rather than a treatment trial, are there separate completed studies you'd recommend I look at that tested actual treatments for my child's specific diagnosis?
4Given that the trial is now terminated, are there any currently active studies measuring IGF-1 prediction models for growth outcomes that might be worth considering, or has this approach been replaced by a different standard of care?
5If IGF-1 monitoring was central to this study's design, how do you currently use IGF-1 levels in my child's care, and should I be asking for those measurements as part of our ongoing evaluation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.